biostudies-literatureUnknown17(10)Milutinovic S<h4>Background</h4>Immune checkpoint inhibitors (ICIs) have been successfully used in the previous decade for the treatment of a variety of malignancies. Adverse events (AEs) can cause many symptoms, most notably cardiac. We analyzed the frequency of these adverse events, comparing pembrolizumab and other ICIs.<h4>Methods</h4>Using the Food and Drug Administration (FDA) adverse event reporting database (FAERS), we searched for all adverse events of interest reported for every ICI included in this study. After obtaining the data, we conducted a disproportionality analysis using the reporting odds ratio (ROR) and the information component (IC).<h4>Results</h4>A total of 6719 ICI-related cardiac adverse events of interest were reported in the database. Serious outcomes were reported in 100% oPharmaceuticals (Basel, Switzerland)1372https://www.ebi.ac.uk/biostudies/studies/S-EPMC11510316biostudies-literaturePembrolizumab-Associated Cardiotoxicity: A Retrospective Analysis of the FDA Adverse Events Reporting System.PMC11510316Dumic ITanasijevic NLopez-Mattei JCao XBegosh-Mayne DEscarcega ROJancic PJokic VPetrovic MStanojevic DRodriguez AMMilutinovic SfalsePembrolizumab-Associated Cardiotoxicity: A Retrospective Analysis of the FDA Adverse Events Reporting System.<h4>Background</h4>Immune checkpoint inhibitors (ICIs) have been successfully used in the previous decade for the treatment of a variety of malignancies. Adverse events (AEs) can cause many symptoms, most notably cardiac. We analyzed the frequency of these adverse events, comparing pembrolizumab and other ICIs.<h4>Methods</h4>Using the Food and Drug Administration (FDA) adverse event reporting database (FAERS), we searched for all adverse events of interest reported for every ICI included in this study. After obtaining the data, we conducted a disproportionality analysis using the reporting odds ratio (ROR) and the information component (IC).<h4>Results</h4>A total of 6719 ICI-related cardiac adverse events of interest were reported in the database. Serious outcomes were reported in 100% o2024-01-01T00:00:00Z2024 Oct2025-04-04T01:24:56.774Z2025-04-04T01:24:56.774ZS-EPMC115103163945901210.3390/ph17101372